Anticipation is high for the forthcoming preliminary data...

Anticipation is high for the forthcoming preliminary data release from our ATH434-202 trial, expected in the first half of this year. ATH434-202 constitutes an open-label Phase 2 Biomarker trial focused on patients with more advanced MSA, a rare neurodegenerative disease for which there are no approved treatments to slow or stop progression. I am hopeful that the scientific endeavors will yield success in improving the lives of those afflicted with this condition. My primary motivation for this investment stems from the distinguished track record of our management team, particularly our MD's involvement in securing 3 FDA approvals within the field of Neurology.

Furthermore, an independent Data Monitoring Committee (DMC) has recently completed its third review of trial data, reasserting their recommendation for the uninterrupted continuation of the ATH434-201 Phase 2 study. Notably, the ATH434-201 Trial remains on track for completion by November 2024, with the eagerly anticipated top-line data scheduled for release in January 2025.